Glecaprevir + pibrentasvir for treatment of hepatitis C.

Expert Opinion on Pharmacotherapy
Andres F Carrion, Paul Martin

Abstract

Glecaprevir/pibrentasvir is a fixed-dose combination regimen of a new generation NS3/4A inhibitor and an NS5A inhibitor with potent antiviral activity against all hepatitis C virus (HCV) genotypes. This regimen offers a shorter course of therapy (8 weeks) for selected patients regardless of genotype and has demonstrated high virological efficacy for retreatment of individuals who previously failed an NS5A containing regimen. Glecaprevir and pibrentasvir are minimally excreted by the kidneys; thus this regimen can safely be used in individuals with severe chronic kidney disease (CKD), including those undergoing hemodialysis. Areas covered: This review covers the mechanism of action, pharmacokinetics, clinical applications, efficacy, and safety profile of glecaprevir/pibrentasvir. It also covers key phase 2 and 3 clinical trials that led to licensure of this regimen. Expert opinion: Glecaprevir/pibrentasvir is the latest antiviral regimen licensed in the United States for treatment of HCV infection. Although several other direct-acting antiviral agents (DAAs) are currently available, glecaprevir/pibrentasvir has some unique characteristics that expand treatment options for HCV infection, including patients with comorbidities such...Continue Reading

References

Dec 21, 2004·Alimentary Pharmacology & Therapeutics·F FabriziG Dulai
Jul 30, 2008·Journal of Hepatology·Paul Martin, Fabrizio Fabrizi
Feb 4, 2010·Clinics in Liver Disease·Helen S Te, Donald M Jensen
Dec 27, 2012·JAMA : the Journal of the American Medical Association·Adriaan J van der MeerHarry L A Janssen
Jul 30, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jane P MessinaEleanor Barnes
Dec 3, 2014·Journal of Hepatology·Rachel H Westbrook, Geoffrey Dusheiko
Jun 18, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jeffrey M CollinsMonica M Farley
Jul 10, 2016·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Cheng WangGeorge Lau
Dec 8, 2016·The American Journal of Gastroenterology·Anjana A PillaiBrian L Pearlman
Dec 25, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jennifer A FlemmingNorah A Terrault
Jan 28, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Fred PoordadFederico J Mensa
Jul 9, 2017·European Journal of Drug Metabolism and Pharmacokinetics·Chih-Wei LinWei Liu
Sep 28, 2017·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Tarik AsselahFederico J Mensa
Oct 12, 2017·The New England Journal of Medicine·Edward GaneFederico J Mensa
Nov 10, 2017·Current Opinion in Pharmacology·Naim AlkhouriFred Poordad

❮ Previous
Next ❯

Citations

Jan 24, 2019·Clinical and Molecular Hepatology·Nadia MarascioCarlo Torti
May 29, 2019·Journal of Managed Care & Specialty Pharmacy·Marina Amaral de Ávila MachadoSasha Bernatsky
Feb 17, 2021·Liver International : Official Journal of the International Association for the Study of the Liver·Tchadine DjaogolUNKNOWN ANRS CO22 Hepather study group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Related Papers

Expert Opinion on Pharmacotherapy
Laurent Alric, Delphine Bonnet
Expert Review of Gastroenterology & Hepatology
Hope Hubbard, Eric Lawitz
Expert Opinion on Drug Safety
Ivan GentileGuglielmo Borgia
© 2022 Meta ULC. All rights reserved